Months af­ter Tmu­ni­ty ground to a halt on clin­i­cal hold, cell ther­a­py pi­o­neer Oz Azam is jump­ing to a stealth start­up

Eight months af­ter ex­ecs at Tmu­ni­ty told us in an ex­clu­sive re­port that the FDA had slapped a clin­i­cal hold on their pipeline pro­grams af­ter an un­ex­pect­ed re­ac­tion to their cell ther­a­pies killed 2 pa­tients and forced them to sus­pend their clin­i­cal tri­als, CEO Us­man “Oz” Azam is head­ed out to take the helm of a stealth biotech.

Most of what we know now is lim­it­ed to what Azam put in his farewell post on LinkedIn, herald­ing the cell ther­a­py field as still “in the be­gin­ning”:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN